Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676769 | 0.86 | TRPV1 (0.70) | TRPV1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL9156203 | 0.85 | CASP6 (0.64) | RXFP1TRPV1MEN1KMT2AGAA | |
| SCHEMBL2747077 | 0.84 | NPC1 (0.71) | RXFP1TRPV1MEN1KMT2AGAA | |
| SCHEMBL4624491 | 0.83 | KDM4E (0.50) | TRPV1MEN1KMT2AGAAPOLB | |
| SCHEMBL25180947 | 0.81 | RAB9A (0.47) | TRPV1MEN1KMT2AGAARAB9A | |
| SCHEMBL26885106 | 0.81 | TRPV1 (0.50) | RXFP1TRPV1MEN1KMT2AGAA | |
| SCHEMBL11876012 | 0.81 | RXFP1 (0.53) | RXFP1TRPV1MEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL10348701 | 0.81 | TRPV1 (0.53) | TRPV1MEN1KMT2AGAAPOLB | |
| SCHEMBL10897449 | 0.81 | RXFP1 (0.53) | RXFP1TRPV1MEN1KMT2AGAA | |
| SCHEMBL28457710 | 0.80 | TRPV1 (0.53) | RXFP1TRPV1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | BAYER CROPSCIENCE AG (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2424838-A1 | PESTICIDAL ARYLPYRROLIDINES | Bayer CropScience AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010124845-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | DDT, AADAC, AHR | RXFP1 2234/4885TRPV1 115/4885MEN1 3664/4885 |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | RXFP1 3198/4885TRPV1 4489/4885MEN1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.